The plans suggest that a retort to the Ebola eruption is finally meeting steam. It is still uncertain if any of these preparations will work, however, and even if they do, they may not be ready in time to help shoot the current endemic.
Starting in January, two serums will be tried in large studies in the West African countries most affected by the eruption, the World Health Organization said on Tuesday. At least three other serums will initiate safety testing in healthy helpers outside the outbreak zone in the first sector of 2015.
One of those three is actually a mixture of two immunizations being established by Johnson & Johnson and Bavarian Nordic, a Danish firm.
Johnson & Johnson declared early Wednesday that it was promising $200 million to the package, including building an equity deal of about $43 million in Bavarian Nordic to help pay for that company’s part in the scheme. It says it plans to begin safety trials in January and hopes to yield one million doses in 2015, with 250,000 accessible for broad claim in clinical tests by May.